481 related articles for article (PubMed ID: 25887773)
21. Efficacy and safety of monoclonal antibody therapies for relapsing remitting multiple sclerosis: A network meta-analysis.
Xu X; Chi S; Wang Q; Li C; Xu B; Zhang J; Chen X
Mult Scler Relat Disord; 2018 Oct; 25():322-328. PubMed ID: 30195200
[TBL] [Abstract][Full Text] [Related]
22. Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients.
Romeo M; Martinelli-Boneschi F; Rodegher M; Esposito F; Martinelli V; Comi G;
Eur J Neurol; 2013 Jul; 20(7):1060-7. PubMed ID: 23425504
[TBL] [Abstract][Full Text] [Related]
23. Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.
Deleu D; Mesraoua B; El Khider H; Canibano B; Melikyan G; Al Hail H; Mhjob N; Bhagat A; Ibrahim F; Hanssens Y
Curr Med Res Opin; 2017 Mar; 33(3):439-458. PubMed ID: 27892723
[TBL] [Abstract][Full Text] [Related]
24. Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis.
Macías-Islas MA; Soria-Cedillo IF; Velazquez-Quintana M; Rivera VM; Baca-Muro VI; Lemus-Carmona EA; Chiquete E
Acta Neurol Belg; 2013 Dec; 113(4):415-20. PubMed ID: 23670405
[TBL] [Abstract][Full Text] [Related]
25. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.
McCool R; Wilson K; Arber M; Fleetwood K; Toupin S; Thom H; Bennett I; Edwards S
Mult Scler Relat Disord; 2019 Apr; 29():55-61. PubMed ID: 30677733
[TBL] [Abstract][Full Text] [Related]
26. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis.
Fox EJ; Rhoades RW
Curr Opin Neurol; 2012 Feb; 25 Suppl():S11-9. PubMed ID: 22398660
[TBL] [Abstract][Full Text] [Related]
27. Safety outcomes of disease-modifying therapies for relapsing-remitting multiple sclerosis: A network meta-analysis.
Lucchetta RC; Leonart LP; Becker J; Pontarolo R; Fernandez-Llimós F; Wiens A
Mult Scler Relat Disord; 2019 Oct; 35():7-15. PubMed ID: 31276913
[TBL] [Abstract][Full Text] [Related]
28. Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis.
Caon C; Din M; Ching W; Tselis A; Lisak R; Khan O
Eur J Neurol; 2006 May; 13(5):471-4. PubMed ID: 16722971
[TBL] [Abstract][Full Text] [Related]
29. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
[TBL] [Abstract][Full Text] [Related]
30. The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations.
Eriksson I; Komen J; Piehl F; Malmström RE; Wettermark B; von Euler M
Eur J Clin Pharmacol; 2018 May; 74(5):663-670. PubMed ID: 29429031
[TBL] [Abstract][Full Text] [Related]
31. Disease-modifying agents for multiple sclerosis and the risk for reporting cancer: A disproportionality analysis using the US Food and Drug Administration Adverse Event Reporting System database.
Stamatellos VP; Siafis S; Papazisis G
Br J Clin Pharmacol; 2021 Dec; 87(12):4769-4779. PubMed ID: 33998034
[TBL] [Abstract][Full Text] [Related]
32. [Update on Current Care Guideline: Multiple sclerosis].
Remes A; Airas L; Atula S; Färkkilä M; Hartikainen P; Koivisto K; Mäenpää E; Ruutiainen J; Sumelahti ML;
Duodecim; 2015; 131(5):500-1. PubMed ID: 26237913
[TBL] [Abstract][Full Text] [Related]
33. Management of relapsing-remitting multiple sclerosis in Qatar: an expert consensus.
Deleu D; Canibaño B; Mesraoua B; Adeli G; Abdelmoneim MS; Ali Y; Elalamy O; Melikyan G; Boshra A
Curr Med Res Opin; 2020 Feb; 36(2):251-260. PubMed ID: 31530036
[TBL] [Abstract][Full Text] [Related]
34. Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment.
Grand'Maison F; Yeung M; Morrow SA; Lee L; Emond F; Ward BJ; Laneuville P; Schecter R
Curr Med Res Opin; 2018 Aug; 34(8):1419-1430. PubMed ID: 29583054
[TBL] [Abstract][Full Text] [Related]
35. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
[TBL] [Abstract][Full Text] [Related]
36. Current evaluation of alemtuzumab in multiple sclerosis.
Coyle PK
Expert Opin Biol Ther; 2014 Jan; 14(1):127-35. PubMed ID: 24289293
[TBL] [Abstract][Full Text] [Related]
37. Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis.
Bell C; Anderson J; Ganguly T; Prescott J; Capila I; Lansing JC; Sachleben R; Iyer M; Fier I; Roach J; Storey K; Miller P; Hall S; Kantor D; Greenberg BM; Nair K; Glajch J
J Pharm Pract; 2018 Oct; 31(5):481-488. PubMed ID: 28847230
[TBL] [Abstract][Full Text] [Related]
38. Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.
McKeage K
CNS Drugs; 2015 May; 29(5):425-32. PubMed ID: 25906331
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
[TBL] [Abstract][Full Text] [Related]
40. A review of the ethics of the use of placebo in clinical trials for relapsing-remitting multiple sclerosis therapeutics.
Solomon AJ; Bernat JL
Mult Scler Relat Disord; 2016 May; 7():109-12. PubMed ID: 27237770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
